Other: iloprost (ventavis inhaled, bayq6256) (DrugBank: Iloprost)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01468545 (ClinicalTrials.gov) | October 2011 | 7/11/2011 | Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System | Prospective, Non-interventional, Multi-centre Study. The Observation Period for Each Subject Covers 1 Year of Treatment. One Initial Visit and 4 Follow-up Visits Every 3 Months and One Extra Educational Reinforcement at Baseline and at 6 Months Will be Given to a Group of Patients. | Pulmonary Arterial Hypertension | Other: Iloprost (Ventavis inhaled, BAYQ6256) | Bayer | Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain) | Completed | 18 Years | N/A | Both | 38 | N/A | Spain |